Citigroup Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target reduced by analysts at Citigroup from $30.00 to $16.50 in a report released on Monday,Benzinga reports. The firm presently has a “sell” rating on the stock. Citigroup’s price objective would indicate a potential downside of 4.29% from the company’s current price.

Several other brokerages also recently commented on HIMS. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. Finally, KeyCorp assumed coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $39.32.

Hims & Hers Health Trading Down 10.8%

NYSE HIMS opened at $17.24 on Monday. Hims & Hers Health has a one year low of $16.35 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a market cap of $3.92 billion, a P/E ratio of 31.93, a P/E/G ratio of 3.21 and a beta of 2.43. The stock’s 50-day moving average is $32.22 and its 200-day moving average is $42.77.

Hims & Hers Health announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This represents a 5.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 129,337 shares of company stock worth $4,651,648. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Capital World Investors lifted its stake in Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp increased its stake in shares of Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after purchasing an additional 132,384 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers pulled its compounded oral semaglutide offering and said it has held “constructive conversations” with stakeholders — a quick damage‑control move that reduces near‑term regulatory exposure. Hims & Hers is scrapping plan for knockoff Wegovy weight-loss pill. Here’s why
• Positive Sentiment: Some analysts/commentators argue the market is overreacting because GLP‑1 weight‑loss was only a portion of revenue and the company’s broader telehealth platform remains intact. That view supports longer‑term recovery potential if legal/regulatory issues are contained. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Some analysts and commentators say the company will survive but warn of a painful reset (“washout”) in the stock while management addresses regulatory/legal fallout. That implies more volatility ahead rather than binary insolvency risk. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit seeking to block Hims & Hers’ compounded semaglutide products and recover damages — this escalates litigation risk and could lead to injunctions or material liability. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: Multiple major outlets report Novo Nordisk’s broader legal offensive and threats that directly target Hims’ GLP‑1 initiative — raising the probability of costly, precedent‑setting litigation. Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
• Negative Sentiment: The FDA issued a warning letter related to Hims’ activities around compounded GLP‑1 products, which increases regulatory uncertainty and could prompt additional enforcement or restrictions. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Analysts have trimmed price targets and ratings (Citigroup, TD Cowen, BofA among others) citing higher legal/regulatory risk and revenue uncertainty — a catalyst for further selling pressure. FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Negative Sentiment: Shareholder litigation/fraud investigations have been announced, potentially adding legal costs and management distraction. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Market reaction: heavy volume, steep declines to multi‑month lows and elevated volatility reflect rapid de‑risking by investors; near‑term sentiment will track legal filings and any FDA follow‑ups. Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.